| FTL | |
|---|---|
| Full Name | Ferritin Light Chain |
| Gene Symbol | FTL |
| Chromosomal Location | 19q13.33 |
| NCBI Gene ID | 2512 |
| OMIM ID | 134790 |
| Ensembl ID | ENSG00000196954 |
| UniProt ID | P02792 |
| Protein Family | Ferritin light chain subunit |
| Associated Diseases | Neuroferritinopathy, Alzheimer's Disease, Parkinson's Disease, NBIA |
FTL encodes the ferritin light chain (FTL) subunit, a critical component of the ferritin protein complex that serves as the primary intracellular iron storage system in eukaryotes. Ferritin is a 24-subunit protein shell (composed of heavy and light chains) capable of storing up to 4,500 iron atoms in a soluble, non-toxic form. The light chain possesses ferroxidase activity that converts toxic Fe²⁺ (ferrous iron) to Fe³⁺ (ferric iron) for safe storage within the protein cavity[1].
Dominant mutations in FTL cause neuroferritinopathy (also called ferritinopathy), a rare form of neurodegeneration with brain iron accumulation (NBIA) characterized by progressive movement disorders and iron deposition in the basal ganglia, cerebellum, and cerebral cortex[2]. Beyond this monogenic disorder, FTL and ferritin function are increasingly recognized as important factors in more common neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[3].
This comprehensive overview addresses the structure, function, and disease associations of FTL, with particular emphasis on its role in neurodegeneration and therapeutic implications.
The FTL gene is located on chromosome 19q13.33 and encodes the light chain subunit of ferritin. The gene structure has been conserved throughout evolution, reflecting its fundamental role in cellular iron homeostasis.
Key genomic features:
FTL combines with the heavy chain (FTH1) to form the functional ferritin complex:
Structural features:
FTL plays a central role in cellular iron homeostasis:
Iron sequestration:
Cellular protection:
The autophagic degradation of ferritin, termed ferritinophagy, is a critical process for iron recycling[4][5]:
NCOA4-mediated ferritinophagy:
Regulation:
Neuroferritinopathy is an autosomal dominant disorder caused by FTL mutations, particularly the 460dupA mutation[6][7]:
Clinical features:
Neuroimaging findings:
Pathogenic mechanisms[8]:
FTL and ferritin are implicated in AD pathogenesis through multiple mechanisms[9][10]:
Amyloid-ferritin relationship:
Iron dysregulation:
Therapeutic implications:
FTL plays important roles in PD pathogenesis[11][12]:
Dopaminergic neuron vulnerability:
Alpha-synuclein interaction:
Therapeutic potential:
Iron accumulation is observed in ALS, with FTL potentially involved[13]:
FTL is widely expressed in the brain, with highest levels in iron-rich regions[3:1]:
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Basal ganglia | Very high | Neurons, glia |
| Substantia nigra | Very high | Dopaminergic neurons |
| Cerebellum | High | Purkinje cells, dentate nucleus |
| Cerebral cortex | Moderate | Pyramidal neurons |
| Hippocampus | Moderate | CA neurons, dentate gyrus |
| Thalamus | Moderate | Various nuclei |
Neuronal expression:
Glial expression:
Management of neuroferritinopathy and related disorders includes[14]:
Iron chelation therapy:
| Drug | Mechanism | Status |
|---|---|---|
| Deferoxamine | Iron chelation | Clinical use |
| Deferasirox | Oral iron chelation | Clinical use |
| Deferiprone | Brain-penetrant | Research |
Antioxidant approaches:
Gene therapy:
Ferritin modulation:
Iron homeostasis normalization:
Transgenic models:
Phenotypic observations:
Neuroferritinopathy models:
AD/PD models:
FTL encodes ferritin light chain, a fundamental component of the ferritin protein complex essential for iron storage and cellular protection against oxidative damage. Mutations in FTL cause neuroferritinopathy, a progressive neurodegenerative disorder characterized by movement disorders, cognitive decline, and iron accumulation in the brain.
Beyond monogenic disease, FTL and ferritin function are increasingly recognized as important factors in common neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS. Iron dysregulation, altered ferritin expression, and impaired ferritinophagy all contribute to disease pathogenesis.
Therapeutic strategies targeting FTL and iron homeostasis include iron chelation, antioxidant therapy, and emerging gene therapy approaches. Understanding FTL function in neurodegeneration continues to inform therapeutic development for these devastating disorders.
Levi S, et al. Ferritinopathy: a neurodegenerative process associated with iron storage. Journal of Neural Transmission Supplement. 2005. ↩︎
Mancuso M, et al. Clinical features and molecular genetics of neuroferritinopathy. Brain. 2020. ↩︎
Ward RJ, et al. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurology. 2014. ↩︎ ↩︎
Wang XS, et al. Molecular mechanisms of ferritinophagy in neurodegeneration. Cellular and Molecular Neurobiology. 2014. ↩︎
Khan MA, et al. Targeting ferritinophagy for neuroprotection. Autophagy. 2019. ↩︎
Curtis AR, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nature Genetics. 2001. ↩︎
Keogh MJ, et al. Genotypic and phenotypic spectrum of FTL-related neurodegeneration with brain iron accumulation. J Med Genet. 2021. ↩︎
Barbaro B, et al. Iron dysregulation and oxidative stress in FTL-linked neurodegeneration. Free Radic Biol Med. 2023. ↩︎
Chen Q, et al. Iron metabolism and ferroptosis in Alzheimer's disease. Frontiers in Neuroscience. 2020. ↩︎
Yang H, et al. Ferritin in the aging brain: mechanisms and implications. Aging Cell. 2021. ↩︎
Moore MN, et al. Ferritinophagy and iron dysregulation in Parkinson's disease. Journal of Neurochemistry. 2019. ↩︎
Angelova M, et al. Iron and ferritin in neurodegenerative diseases. Neurobiology of Disease. 2019. ↩︎
Chio A, et al. Iron accumulation in ALS: cause or consequence?. Journal of Neurology Neurosurgery & Psychiatry. 2019. ↩︎
Sawicka M, et al. Therapeutic targeting of iron accumulation in FTL-related neurodegeneration. Molecular Therapy. 2024. ↩︎